COMPAGNIE CHARGEURS INVEST (CRI.PA) Fundamental Analysis & Valuation

EPA:CRI • FR0000130692

Current stock price

8.4 EUR
+0.07 (+0.84%)
Last:

This CRI.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRI.PA Profitability Analysis

1.1 Basic Checks

  • In the past year CRI has reported negative net income.
  • CRI had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: CRI reported negative net income in multiple years.
  • In multiple years CRI reported negative operating cash flow during the last 5 years.
CRI.PA Yearly Net Income VS EBIT VS OCF VS FCFCRI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

1.2 Ratios

  • CRI has a Return On Assets of -2.49%. This is in the lower half of the industry: CRI underperforms 70.59% of its industry peers.
  • The Return On Equity of CRI (-9.87%) is worse than 70.59% of its industry peers.
Industry RankSector Rank
ROA -2.49%
ROE -9.87%
ROIC N/A
ROA(3y)-0.61%
ROA(5y)0.79%
ROE(3y)-2.6%
ROE(5y)2.31%
ROIC(3y)N/A
ROIC(5y)N/A
CRI.PA Yearly ROA, ROE, ROICCRI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

1.3 Margins

  • CRI has a Gross Margin of 29.62%. This is in the lower half of the industry: CRI underperforms 76.47% of its industry peers.
  • CRI's Gross Margin has improved in the last couple of years.
  • CRI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.99%
GM growth 5Y2.14%
CRI.PA Yearly Profit, Operating, Gross MarginsCRI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

4

2. CRI.PA Health Analysis

2.1 Basic Checks

  • CRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRI has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CRI has been increased compared to 5 years ago.
  • Compared to 1 year ago, CRI has a worse debt to assets ratio.
CRI.PA Yearly Shares OutstandingCRI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
CRI.PA Yearly Total Debt VS Total AssetsCRI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • CRI has a Debt/Equity ratio of 1.56. This is a high value indicating a heavy dependency on external financing.
  • CRI's Debt to Equity ratio of 1.56 is in line compared to the rest of the industry. CRI outperforms 41.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.3%
CRI.PA Yearly LT Debt VS Equity VS FCFCRI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.42 indicates that CRI has no problem at all paying its short term obligations.
  • CRI has a better Current ratio (2.42) than 94.12% of its industry peers.
  • A Quick Ratio of 2.07 indicates that CRI has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.07, CRI belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.07
CRI.PA Yearly Current Assets VS Current LiabilitesCRI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

1

3. CRI.PA Growth Analysis

3.1 Past

  • The earnings per share for CRI have decreased strongly by -410.75% in the last year.
  • The Revenue for CRI has decreased by -42.48% in the past year. This is quite bad
  • The Revenue for CRI have been decreasing by -12.58% on average. This is quite bad
EPS 1Y (TTM)-410.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-241.3%
Revenue 1Y (TTM)-42.48%
Revenue growth 3Y-17%
Revenue growth 5Y-12.58%
Sales Q2Q%-86.63%

3.2 Future

  • CRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.89% yearly.
  • The Revenue is expected to decrease by -13.13% on average over the next years. This is quite bad
EPS Next Y175.41%
EPS Next 2Y44.29%
EPS Next 3Y23.89%
EPS Next 5YN/A
Revenue Next Year-24.7%
Revenue Next 2Y-11.26%
Revenue Next 3Y-13.13%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CRI.PA Yearly Revenue VS EstimatesCRI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
CRI.PA Yearly EPS VS EstimatesCRI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5

4

4. CRI.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRI. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 9.90 indicates a reasonable valuation of CRI.
  • 94.12% of the companies in the same industry are more expensive than CRI, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of CRI to the average of the S&P500 Index (38.16), we can say CRI is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.9
CRI.PA Price Earnings VS Forward Price EarningsCRI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • 64.71% of the companies in the same industry are cheaper than CRI, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.09
CRI.PA Per share dataCRI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • CRI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CRI's earnings are expected to grow with 23.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.29%
EPS Next 3Y23.89%

1

5. CRI.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.53%, CRI has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 2.95, CRI is paying slightly less dividend.
  • CRI's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.53%

5.2 History

  • The dividend of CRI decreases each year by -14.15%.
Dividend Growth(5Y)-14.15%
Div Incr Years1
Div Non Decr Years1
CRI.PA Yearly Dividends per shareCRI.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2025 2026 0.5 1 1.5

5.3 Sustainability

  • CRI has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-12.08%
EPS Next 2Y44.29%
EPS Next 3Y23.89%
CRI.PA Yearly Income VS Free CF VS DividendCRI.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

CRI.PA Fundamentals: All Metrics, Ratios and Statistics

COMPAGNIE CHARGEURS INVEST

EPA:CRI (4/15/2026, 5:18:35 PM)

8.4

+0.07 (+0.84%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryIndustrial Conglomerates
Earnings (Last)03-19
Earnings (Next)N/A
Inst Owners4.65%
Inst Owner ChangeN/A
Ins Owners64.2%
Ins Owner ChangeN/A
Market Cap209.08M
Revenue(TTM)419.70M
Net Income(TTM)-24.00M
Analysts74.29
Price Target12.07 (43.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.53%
Yearly Dividend0.12
Dividend Growth(5Y)-14.15%
DP-12.08%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.74%
PT rev (3m)4.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.66%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.85%
Revenue NY rev (3m)-31.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.9
P/S 0.5
P/FCF N/A
P/OCF 9.68
P/B 0.86
P/tB 11.3
EV/EBITDA 20.09
EPS(TTM)-0.99
EYN/A
EPS(NY)0.85
Fwd EY10.1%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)0.87
OCFY10.33%
SpS16.86
BVpS9.77
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -2.49%
ROE -9.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.62%
FCFM N/A
ROA(3y)-0.61%
ROA(5y)0.79%
ROE(3y)-2.6%
ROE(5y)2.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.99%
GM growth 5Y2.14%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF N/A
Debt/EBITDA 14.09
Cap/Depr 112.9%
Cap/Sales 7.51%
Interest Coverage N/A
Cash Conversion 80.3%
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.07
Altman-Z N/A
F-Score5
WACC6.3%
ROIC/WACCN/A
Cap/Depr(3y)84.29%
Cap/Depr(5y)67.14%
Cap/Sales(3y)4.52%
Cap/Sales(5y)3.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-410.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-241.3%
EPS Next Y175.41%
EPS Next 2Y44.29%
EPS Next 3Y23.89%
EPS Next 5YN/A
Revenue 1Y (TTM)-42.48%
Revenue growth 3Y-17%
Revenue growth 5Y-12.58%
Sales Q2Q%-86.63%
Revenue Next Year-24.7%
Revenue Next 2Y-11.26%
Revenue Next 3Y-13.13%
Revenue Next 5YN/A
EBIT growth 1Y-102.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.24%
EBIT Next 3Y5.57%
EBIT Next 5YN/A
FCF growth 1Y-134.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.46%
OCF growth 3YN/A
OCF growth 5Y-21.62%

COMPAGNIE CHARGEURS INVEST / CRI.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRI.PA.


What is the valuation status for CRI stock?

ChartMill assigns a valuation rating of 4 / 10 to COMPAGNIE CHARGEURS INVEST (CRI.PA). This can be considered as Fairly Valued.


How profitable is COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

COMPAGNIE CHARGEURS INVEST (CRI.PA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for COMPAGNIE CHARGEURS INVEST?

The Earnings per Share (EPS) of COMPAGNIE CHARGEURS INVEST (CRI.PA) is expected to grow by 175.41% in the next year.